Questions over Novo Nordisk $1bn weight loss drug
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen,
Weight-loss drugs are supposed to be forever. Until they run out.
A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the drug continuously for about a year and 4 months and then stopping. It found that about two-thirds regained the weight they lost. A similarly designed study had comparable results for tirzepatide (Zepbound).
Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,
Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs
Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is scheduled to testify on Capitol Hill Tuesday.
Novo Nordisk's Experimental Oral Drug Reports 'Remarkable' Weight Loss, Early Data Shows
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain,
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.
Questions over Novo Nordisk $1bn weight loss drug after Phase IIa trial
Novo Nordisk acquired monlunabant in a $1bn deal last year, but the Phase IIa trial raises questions over the efficacy and safety ratio.
2 Weight-Loss Stocks That Could Rocket Higher This Year
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
Noom will submit an official statement to the congressional record at Tuesday’s Senate hearing with three specific ...
Green tea for fueling weight loss? Experts reveal the skinny truth
Recently, social media posts have been buzzing about green tea as a way to shed pounds without the medication and high costs.
A Trainer's Realistic 3x/Week Workout for Weight Loss
A trainer outlines how to perform his ultimate three-day workout for weight loss that seamlessly fits into any schedule.
FierceBiotech19m
Metsera links long-acting GLP-1 shot to 7.5% weight loss at 36 days, mulls monthly dosing
Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...
verywellhealth21h
Is Yoga Good for Weight Loss?
If you want to practice yoga for weight loss, aim to exercise as often as possible. An intense hour-long practice at least ...
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...
Medscape3h
Considering Eating Disorder Potential When Prescribing Weight Loss Drugs to Teens
Physicians fear use of weight loss drugs in teens will increase or exacerbate eating disorder cases, adding complexity to ...